title: [The risk of recurrence following the thyrostatic treatment of immunogenic and nonimmunogenic hyperthyroidism].
abstract: Data of 196 patients treated for hyperthyroidism exclusively with antithyroid drugs were analyzed retrospectively concerning the relapse rate within a follow-up period of four years. Patients were subdivided for primary or recurrent disease, and for immunogenic or non-immunogenic hyperthyroidism, respectively. In immunogenic as well as in non-immunogenic hyperthyroidism, the relapse rate was significantly lower for patients with primary disease (35% and 52%, respectively) compared to those with recurrent hyperthyroidism (82%, p less than 0.001 and 83%, p less than 0.001, respectively). In patients with primary disease, clinical, biochemical and scintigraphic parameters were tested with respect to their capability of predicting a relapse. For immunogenic hyperthyroidism the highest relapse rates were observed in young patients and in those with large goitres, whereas for non-immunogenic hyperthyroidism they were highest in old patients, in those with nodular goitres and in those without an increased urinary iodine excretion at the time of diagnosing hyperthyroidism.
authors.affiliation: Nuklearmedizinische Abteilung, Universität Göttingen, Bundesrepublik Deutschland.
authors.forename: E
authors.initials: E
authors.lastname: Voth
authors.forename: N
authors.initials: N
authors.lastname: Dickmann
authors.forename: H
authors.initials: H
authors.lastname: Schicha
authors.forename: D
authors.initials: D
authors.lastname: Emrich
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence; D012306:Risk; D013974:Thyroxine / Q000627:therapeutic use*
chemical_list: D008713:Methimazole; D013974:Thyroxine
vernacular_title: Rezidivrisiko nach thyreostatischer Behandlung immunogener und nicht-immunogener Hyperthyreosen.